Pfizer ‘intensively researching’ long-lasting COVID-19 vaccine

Pfizer’s CEO said the company is currently focused on developing a COVID-19 vaccine that offers protection for at least one year in anticipation that longer lasting efficacy will encourage more people to stay up to date with vaccine recommendations. 

Advertisement

“I recognize that the biggest challenge for the healthcare system right now will become the compliance with vaccination recommendations,” Albert Bourla, Pfizer’s chairman and CEO, told attendees at Fortune’s Brainstorm Health conference on May 10. 

He said people will be less inclined to stay up to date with boosters if they only offer sufficient protection for several months.

“[That’s] why working on an annual vaccine, or a vaccine that will last at least a year, is the holy grail right now, and we are very intensively researching this,” Mr. Bourla said. 

A recent study from researchers at Oakland, Calif.-based Kaiser Permanente found booster protection against hospitalization wanes after three months, falling from about 80 percent to 90 percent to 55 percent.

To read the CDC’s current booster recommendations, click here. 

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.